Annual report pursuant to Section 13 and 15(d)

REVENUES (Tables)

v3.22.0.1
REVENUES (Tables)
12 Months Ended
Dec. 31, 2021
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

Year Ended December 31,

2021

    

2020

    

2019

Product sales:

Gross product sales

$

81,186

$

76,470

$

53,082

Discounts and allowances

(18,176)

 

(14,774)

 

(9,310)

Total product sales, net

63,010

61,696

43,772

Revenues from collaborations:

License revenues

70,553

40,358

8,696

Development milestones

1,875

 

2,100

 

5,500

Research and development services and others

3,298

 

4,467

 

1,320

Total revenues from collaborations

75,726

46,925

15,516

Government contract

10,500

Total revenues

$

149,236

$

108,621

$

59,288

Schedule of product revenue allowance and reserve categories

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2021

    

$

2,461

 

$

2,115

$

1,489

$

6,065

Provision related to current period sales

10,731

5,036

1,021

16,788

Credit or payments made during the period

(9,788)

(4,657)

(493)

(14,938)

Balance as of December 31, 2021

 

$

3,404

$

2,494

$

2,017

$

7,915

Chargebacks,

Government

Discounts and

and Other

Fees

Rebates

Returns

Total

Balance as of January 1, 2020

    

$

1,293

 

$

1,801

$

238

$

3,332

Provision related to current period sales

8,149

4,231

950

13,330

Adjustment related to prior period sales

(75)

(490)

565

Credit or payments made during the period

(6,906)

(3,427)

(264)

(10,597)

Balance as of December 31, 2020

 

$

2,461

$

2,115

$

1,489

$

6,065

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of the total net product sales and revenues from collaborations:

Year Ended December 31,

2021

    

2020

2019

Lilly

48%

McKesson Specialty Care Distribution Corporation

20%

23%

30%

ASD Healthcare and Oncology Supply

17%

30%

37%

Grifols

*

41%

*